| European Case Law Identifier: | ECLI:EP:BA:2012:T167711.20121127 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 27 November 2012 | ||||||||
| Case number: | T 1677/11 | ||||||||
| Application number: | 00108479.7 | ||||||||
| IPC class: | C07D 401/12 A61K 31/44 A61P 1/04 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | The sodium salt of the (-)-enantiomer of omeprazole | ||||||||
| Applicant name: | AstraZeneca AB | ||||||||
| Opponent name: | Farmaprojects, S.A. Wittkopp, Alexander Teva Pharmaceutical Industries Ltd. Actavis Group hf. LEK Pharmaceuticals d.d. Hörnchen, Ulrich, Dr. |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of partiality objections (no) Main request, allowable Added matter (no) Sufficiency (yes), starting material retrievable from Chemical Abstracts Novelty (yes), specific salt Inventive step (yes), post-published evidence (yes), unexpected advantage |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t111677eu1.html
Date retrieved: 17 May 2021